American Thoracic Society - Sanofi Investor Call

Primary, Secondary, and Other Endpoints Baseline Primary endpoint Secondary and other endpoints Annualized rate of moderate-to-severe exacerbations from baseline to Week 52 Change from baseline to Week 12 and 52 in lung function Change from baseline to Week 52 in SGRQ % of patients with SGRQ improvement ≥4 points at Week 52 Change from baseline to Week 52 in E-RS:COPD total score ATS 2023 Week 52 22 22

View entire presentation